Tvardi Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TVRD research report →
About the company
Tvardi Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
- CEO
- Imran Alibhai
- IPO
- 2014
- Employees
- 12
- HQ
- Sugar Land, TX, US
Price Chart
- Market Cap
- $18.95M
- P/E
- -1.27
- P/S
- 0.00
- P/B
- 1.31
- EV/EBITDA
- 0.05
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -64.17%
- ROIC
- -200.59%
- Revenue
- $0 · -100.00%
- Net Income
- $-18,214,000 · 74.30%
- EPS
- $-2.46 · 94.72%
- Op Income
- $-26,748,000
- FCF YoY
- 62.08%
- 52W High
- $43.65
- 52W Low
- $1.50
- 50D MA
- $3.10
- 200D MA
- $7.11
- Beta
- 0.39
- Avg Volume
- 160.61K
Get TickerSpark's AI analysis on TVRD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 9, 26 | Shiff Susan Ph.D. | other | 6,000 |
| Jun 9, 26 | Smith Cynthia | other | 6,000 |
| Jun 9, 26 | Shah Sujal | other | 6,000 |
| Jun 9, 26 | HALL WALLACE L JR | other | 6,000 |
| Jun 9, 26 | WYZGA MICHAEL S | other | 6,000 |
| Jan 29, 26 | O'Brien Stephen Paul | other | 15,000 |
| Jan 29, 26 | Conn Avi Daniel | other | 45,000 |
| Jan 29, 26 | Kauh John Saewook M.D. | other | 45,000 |
| Jan 29, 26 | Alibhai Imran Nizamudin | other | 115,000 |
| Dec 16, 25 | O'Brien Stephen Paul | other | 4,000 |
Our TVRD coverage
Recent articles, reports, and earnings notes.
No research on TVRD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TVRD report →Similar companies
Peers in the same neighborhood.